The Golden Lounge

[Theo]

PBMD Thinking I'm glad I hung on:

Highlights from the PDF news release


Prima's most advanced LAG based product, IMP321 generated more than double the expected response rate in HER negative metastatic breast cancer in a Phase IIa clinical trial. Prima is currently preparing to in itiate a Phase IIb study based on scientific advice from the
European Medicines Agency which will commence during 2nd half of 2015.

Existing partnerships for LAG programs with GSK and Novartis are
currently in ongoing clinical trials or close to starting.Those
programs are funded by the respective development partners.

Marc Voigt, CEO of Prima BioMed said: “LAG is widely recognised within the industry as being one of the important targets in immunooncology therapies, which are increasingly attracting
the attention of global pharma companies.

Consolidation of the CVac program will reduce Prima’s CVac related annual cash outflows significantly.